156003 20240328115555.0 10.3390/pharmaceutics13030379 doi pmid:33809385 pmid pmc:PMC7999378 pmc altmetric:102431678 altmetric DZNE-2021-01135 English 610 Scuteri, Damiana 0000-0001-5846-7058 0 Development and Translation of NanoBEO, a Nanotechnology-Based Delivery System of Bergamot Essential Oil Deprived of Furocumarins, in the Control of Agitation in Severe Dementia. Basel 2021 MDPI article DRIVER Output Types/Journal article DataCite Journal Article journal journal PUB:(DE-HGF)16 1711616219_27787 PUB:(DE-HGF) ARTICLE BibTeX JOURNAL_ARTICLE ORCID Journal Article 0 EndNote Dementia is one of the most common causes of disability worldwide characterized by memory loss, cognitive impairment, and behavioral and psychological symptoms (BPSD), including agitation. Treatment of the latter consists of the off-label use of harmful atypical antipsychotics, though a significant reduction is afforded by pain control. The use of an essential oil endowed with analgesic properties and devoid of toxicity would represent an important option for the management of agitation in dementia. Therefore, the aim of this study was to engineer a nanotechnology delivery system based on solid lipid nanoparticles loaded with bergamot essential oil (BEO) and devised in the pharmaceutical form of an odorless cream (NanoBEO) to confirm its analgesic efficacy for further development and application to control agitation in dementia. BEO has proven strong antinociceptive and anti-allodynic properties and, in its bergapten-free form, it is completely devoid of phototoxicity. NanoBEO has been studied in vivo confirming the previously reported analgesic activity of BEO to which is now added its anti-itching properties. Due to the nanotechnology delivery system, the stability of titrated BEO components is guaranteed. Finally, the latter invention, currently under patent consideration, is smell-devoid allowing efficacy and safety to be established in double-blind clinical trials; until now the latter studies have been impeded in aromatherapy by the strong odor of essential oils. A clinical trial NCT04321889 has been designed to provide information about the efficacy and safety of NanoBEO on agitation and pain in patients suffering from severe dementia. 351 - Brain Function (POF4-351) G:(DE-HGF)POF4-351 POF4-351 POF IV 0 Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de BPSD Other agitation Other dementia Other essential oil of bergamot Other nanotechnology delivery system Other pain Other Cassano, Roberta 0000-0001-6980-6799 1 Trombino, Sonia 2 Russo, Rossella 0000-0001-8758-6523 3 Mizoguchi, Hirokazu 4 Watanabe, Chizuko 5 Hamamura, Kengo 0000-0001-9146-8554 6 Katsuyama, Soh 7 Komatsu, Takaaki 8 Morrone, Luigi Antonio 9 Rombolà, Laura 0000-0002-1727-3158 10 Adornetto, Annagrazia 0000-0003-1869-2642 11 Laganà, Annarita S 12 Corasaniti, Maria Tiziana 0000-0001-6472-0697 13 Tonin, Paolo 14 Sakurada, Shinobu 15 Sakurada, Tsukasa 16 Nicotera, Pierluigi P:(DE-2719)2010732 17 dzne Bagetta, Giacinto 0000-0001-8540-6218 18 Lipid Nanoparticles in the Treatment of Neurological and Other Aging Related Disorders 10.3390/pharmaceutics13030379 Vol. 13, no. 3, p. 379 - PERI:(DE-600)2527217-2 3 379 Pharmaceutics 13 2021 1999-4923 OpenAccess http://pub.dzne.de/record/156003/files/DZNE-2021-01135.pdf OpenAccess pdfa http://pub.dzne.de/record/156003/files/DZNE-2021-01135.pdf?subformat=pdfa oai:pub.dzne.de:156003 openaire open_access VDB driver dnbdelivery Deutsches Zentrum für Neurodegenerative Erkrankungen I:(DE-588)1065079516 DZNE 17 P:(DE-2719)2010732 DE-HGF Gesundheit Neurodegenerative Diseases G:(DE-HGF)POF4-350 G:(DE-HGF)POF4-351 G:(DE-HGF)POF4 G:(DE-HGF)POF4-300 G:(DE-HGF)POF Brain Function 0 2021 DBCoverage StatID:(DE-HGF)0200 StatID SCOPUS 2022-11-25 Creative Commons Attribution CC BY (No Version) LIC:(DE-HGF)CCBYNV V:(DE-HGF) DOAJ 2021-05-04 DBCoverage StatID:(DE-HGF)1050 StatID BIOSIS Previews 2022-11-25 DBCoverage StatID:(DE-HGF)1190 StatID Biological Abstracts 2021-05-04 DBCoverage StatID:(DE-HGF)0600 StatID Ebsco Academic Search 2022-11-25 JCR StatID:(DE-HGF)0100 StatID PHARMACEUTICS : 2021 2022-11-25 DBCoverage StatID:(DE-HGF)0501 StatID DOAJ Seal 2022-08-24T11:04:26Z WoS StatID:(DE-HGF)0113 StatID Science Citation Index Expanded 2021-05-04 DBCoverage StatID:(DE-HGF)0500 StatID DOAJ 2022-08-24T11:04:26Z DBCoverage StatID:(DE-HGF)0300 StatID Medline 2022-11-25 DBCoverage StatID:(DE-HGF)0150 StatID Web of Science Core Collection 2022-11-25 OpenAccess StatID:(DE-HGF)0510 StatID Peer Review StatID:(DE-HGF)0030 StatID ASC 2022-11-25 Article Processing Charges StatID:(DE-HGF)0561 StatID 2021-05-04 IF >= 5 StatID:(DE-HGF)9905 StatID PHARMACEUTICS : 2021 2022-11-25 DBCoverage StatID:(DE-HGF)0160 StatID Essential Science Indicators 2021-05-04 DBCoverage StatID:(DE-HGF)0199 StatID Clarivate Analytics Master Journal List 2022-11-25 Fees StatID:(DE-HGF)0700 StatID 2021-05-04 I:(DE-2719)5000018 AG Nicotera Synaptic Connectivity and Neurodegeneration 0 journal VDB UNRESTRICTED I:(DE-2719)5000018 FullTexts